AMBR vs NVDA

AMBR's Piotroski F-Score of 2/9 indicates severe financial distress, with weak operational and profitability fundamentals. The company exhibits extreme negative profit margins (-296.23%) despite a 1934.6% YoY revenue surge, signaling unsustainable growth driven by cost inefficiencies. The absence of an Altman Z-Score and a critically low quick ratio (0.18) raise serious concerns about liquidity and solvency. Although the debt/equity ratio is 0.00, the lack of operating cash flow and free cash flow data further undermines financial health. The stock trades at a premium valuation (Price/Sales: 49.46) with no earnings support, making it highly speculative.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.